A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy

Y Watanabe1, T Kojima, S Kagawa

  • 1Center for Gene and Cell Therapy, Okayama University Hospital, Okayama, Japan.

Oncogene
|November 26, 2009
PubMed

Insights

Oncolytic adenovirus therapy shows promise for malignant pleural mesothelioma (MPM). Combining a telomerase-specific oncolytic adenovirus with a heparanase-expressing adenovirus enhanced antitumor effects in preclinical models.

Area of Science:

  • Oncology
  • Virology
  • Gene Therapy

Background:

  • Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related cancer with poor prognosis.
  • Conventional therapies are often ineffective against MPM.
  • Locoregional virotherapy offers a potential treatment strategy due to direct intrapleural delivery.

Purpose of the Study:

  • To evaluate the efficacy of a telomerase-specific oncolytic adenovirus (OBP-301) against human mesothelioma cells.
  • To investigate the potential of combining OBP-301 with a heparanase-expressing adenovirus to overcome extracellular matrix barriers.

Main Methods:

  • In vitro infection and killing of human mesothelioma cells by OBP-301.
  • Intrathoracic administration of OBP-301 in a mouse model of human mesothelioma.
  • Assessment of viral replication using fluorescence imaging.
  • Evaluation of combined OBP-301 and heparanase-expressing adenovirus therapy in an orthotopic pleural dissemination model.

Main Results:

  • OBP-301 efficiently infected and replicated within human mesothelioma cells, leading to cell death.
  • Intrathoracic OBP-301 treatment significantly reduced tumor burden in mice.
  • Combined therapy with OBP-301 and heparanase-expressing adenovirus demonstrated enhanced antitumor effects without observed toxicity.

Conclusions:

  • Telomerase-specific oncolytic adenovirus OBP-301 is effective against malignant pleural mesothelioma.
  • Dual virotherapy combining OBP-301 with heparanase-expressing adenovirus may improve treatment efficacy by enhancing tumor penetration.
  • This combination strategy holds potential for preventing and treating pleural dissemination of MPM.